ZA913728B - Method for preventing onset of restenosis after angioplasty employing an ace inhibitor - Google Patents

Method for preventing onset of restenosis after angioplasty employing an ace inhibitor

Info

Publication number
ZA913728B
ZA913728B ZA913728A ZA913728A ZA913728B ZA 913728 B ZA913728 B ZA 913728B ZA 913728 A ZA913728 A ZA 913728A ZA 913728 A ZA913728 A ZA 913728A ZA 913728 B ZA913728 B ZA 913728B
Authority
ZA
South Africa
Prior art keywords
angioplasty
restenosis
employing
ace inhibitor
preventing onset
Prior art date
Application number
ZA913728A
Other languages
English (en)
Inventor
Miguel A Ondetti
A Ondetti Miguel
A K Gunnar Aberg
K Gunnar Aberg A
Patricia Ferrer
Ferrer Patricia
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of ZA913728B publication Critical patent/ZA913728B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA913728A 1990-05-31 1991-05-16 Method for preventing onset of restenosis after angioplasty employing an ace inhibitor ZA913728B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53200090A 1990-05-31 1990-05-31

Publications (1)

Publication Number Publication Date
ZA913728B true ZA913728B (en) 1992-02-26

Family

ID=24119992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913728A ZA913728B (en) 1990-05-31 1991-05-16 Method for preventing onset of restenosis after angioplasty employing an ace inhibitor

Country Status (8)

Country Link
EP (1) EP0459318A3 (xx)
JP (1) JPH04235924A (xx)
AU (1) AU642492B2 (xx)
CA (1) CA2042159A1 (xx)
HU (1) HUT59010A (xx)
IE (1) IE911779A1 (xx)
PT (1) PT97807A (xx)
ZA (1) ZA913728B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
CA2119019A1 (en) * 1991-09-16 1993-04-01 Harry R. Davis Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin

Also Published As

Publication number Publication date
JPH04235924A (ja) 1992-08-25
EP0459318A3 (en) 1993-02-24
PT97807A (pt) 1992-04-30
EP0459318A2 (en) 1991-12-04
AU7728191A (en) 1991-12-05
IE911779A1 (en) 1991-12-04
CA2042159A1 (en) 1991-12-01
AU642492B2 (en) 1993-10-21
HU911814D0 (en) 1991-12-30
HUT59010A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
ZA913725B (en) Method for preventing onset of restenosis after angioplasty employing pravastatin
EP0693083A4 (en) ALPHACETOAMIDE DERIVATIVES USEFUL AS THROMBOSIS INHIBITORS
EP0474540A3 (en) Scale inhibitor for calcium-type scale
NO960339D0 (no) Fremgangsmåte for å inhibere restenose
PL308553A1 (en) Inhibitors of farnesil-protein transferase
EP0612249A4 (en) Methods of inhibiting restenosis.
EP0671944A4 (en) TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR.
HU9202420D0 (en) An activating agent for biosynthesis of gen macrolids
EP0651766A4 (en) INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
EP0599514A3 (en) Pyranoquinoline derivatives as inhibitors of cell proliferation.
EP0459318A3 (en) Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
AU2640488A (en) Method for preventing or treating anxiety employing an ace inhibitor
GB9318000D0 (en) Inhibition of vascular restenosis
JPS6463595A (en) Ribonucleotide reductase inhibitor
AU7331194A (en) At-2 antagonist inhibition of vascular restenosis
EP0688225A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING SUPPLEMENT ACTIVATION
PL326294A1 (en) Method of retarding the inhibitor 1 of plasminogene activator
EP0411395A3 (en) Use of ace inhibitors for atherosclerosis-prophylaxis
ZA918719B (en) Ester inhibitors
ZA92717B (en) Process for the shortening of the access time
HK113596A (en) Method of reducing access time
EP0496343A3 (en) Method for surface-release coating and coating agent therefor
EP0543936A4 (en) Renin inhibitors
PL310620A1 (en) Method of obtaining condenset carbapenemic derivatives
EP0528515A3 (en) Hmg-coa reductase inhibitors in the prevention of restenosis following coronary angioplasty